Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Ipsen provides update on CONTACT-02 Phase III trial in metastatic…
Trial investigating Cabometyx ®(cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet statistical significanceIpsen will not pursue regulatory submissions for the combination regimen in countries where we have commercialization rights (outside of the US and Japan)We remain confident in the proven profile of Cabometyx as a monotherapy and in combination with...
Nasdaq GlobeNewswire
15/09/2024
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor…
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan(Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohortResponses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m 2in patients with advanced ovarian cancer Genmab A/S(Nasdaq: GMAB)announced today new data from the Phase...
Nasdaq GlobeNewswire
15/09/2024
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the…
The Breakthrough Therapy designation is based on the significant improvement in efficacy metrics demonstrated by the sublingual tablets in a previous clinical study. The data from a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study in China for the treatment of AIS demonstrated that Sanbexin sublingual tablets significantly improved neurological recovery and independent living ability in patients with AIS compared to placebo, meeting the expected…
PR Newswire
14/09/2024
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly…
Phase Ia Study Results Phase Ia Study Results This placebo-controlled and active-comparator-controlled, single-center, single-dose, randomized, dose-escalation study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GZR4 in healthy adult male participants. The study was conducted following a dose-escalation design, starting from lower doses and progressively increasing to higher doses. Participants in cohorts 1-4 randomly receiving a...
PR Newswire
14/09/2024
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society…
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. 14 September 2024 Avacta Group plc (“Avacta” or “the Group” or...
Nasdaq GlobeNewswire
14/09/2024
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every…
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting -…
Nasdaq GlobeNewswire
14/09/2024
Fagron completes share buy-back program
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period from 9 September 2024 through 13 September 2024, Fagron purchased 45,000 of its owns shares at an average price of € 19.10 per share corresponding to a total amount of € 859,324.10. A total of 150,000 Fagron shares have been repurchased under the buy-back program at...
Nasdaq GlobeNewswire
13/09/2024
Virbac : Half-yearly financial report 2024
Please find attached 2024 Half-yearly financial report of Virbac Attachment Half-Yearly Financial Report_2024 for publication
Nasdaq GlobeNewswire
13/09/2024
Virbac : Public release of the Half-Year Financial Report at 30 June 2024.
Public release of the Half-Year Financial Report at 30 June 2024.The Group released and filed its 2024 half-year financial report with the French “Autorité des marchés financiers”.The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports”. Attachment Public release of the Half-Year Financial Report_06.24
Nasdaq GlobeNewswire
13/09/2024
Virbac : the board of directors announces a capital reduction through…
During the meeting held on September 13, 2024, the board of directors, acting on the authorization granted by the combined shareholders' meeting on June 20, 2023, decided to reduce the share capital of Virbac by canceling 67,340 treasury shares. These shares were acquired during 2023 under the share buyback program authorized by the same shareholders' meeting.As of today, the share capital of Virbac amounts to €10,448,325, represented by 8,390,660 shares of €1.25, fully...
Nasdaq GlobeNewswire
13/09/2024
Virbac: Information on the departure of Sébastien Huron
At its meeting on September 13, 2024, the board of directors acknowledged the resignation of Sébastien Huron, effective as of September 27, 2024, from his positions as chief executive officer of Virbac and director of Virbac Limited (UK).On the recommendation of the appointments and compensation committee, the board of directors has decided on the financial terms of Sébastien Huron's departure, as set out below.Fixed compensation for 2024 In accordance with the compensation policy...
Nasdaq GlobeNewswire
13/09/2024
Virbac 2024 half-year results
Exceptional business momentum in the first half, with revenue up 16.1% at constant exchange ratesStrong growth in adjusted current operating income 1 +3.4 points compared with 2023 to reach a record level at 21.4% of revenue2024 targets confirmed Revenue growth expected between 7% and 9% at constant exchange rates and scopeAdjusted current operating income 1expected to be around 16% compared with 15.1% in 2023 CONSOLIDATED FIGURES AS AT JUNE 30...
Nasdaq GlobeNewswire
13/09/2024
Disclosure of large shareholding and mandatory notification of trade in Vistin…
Saga Pure ASA has on 13 September 2024 purchased 250,000 shares in Vistin Pharma ASA at NOK 25.13 per share. After the transaction Saga Pure ASA has a holding of 650,000 shares, corresponding to 1.47% ownership. Saga Pure ASA is closely associated with board member Øystein Stray Spetalen.After the transaction Øystein Stray Spetalen and associated companies will have a total holding of 2,224,401 shares, corresponding to 5.02 % ownership.Attachment 20240913_Notification of trade_Saga...
Nasdaq GlobeNewswire
13/09/2024
Needle Holder Market: USD 367.3M in 2024 to USD 530.3M by 2029, CAGR 7.6% |…
Browse in-depth TOC on "Needle Holder Market" Browse in-depth TOC on "Needle Holder Market" 280 - Tables40 - Figures250 - Pages Market Segmentation by Type The needle holder market is categorized into several types: Castroviejo, Olsen-Hegar, Mayo-Hegar, Derf, Crile-Wood, and others. As of 2023, the Mayo-Hegar Needle Holder holds the largest market share due to its widespread use in various surgeries such as general, cardiovascular, and orthopedic. The Castroviejo...
PR Newswire
13/09/2024
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European…
“Combined, the findings that will be showcased represent key steps along the developmental pathway of Cube's “go-to-market” strategy for its open-source AI platform as a service provider to many potential private sector partners and (academic) hospitals, as well as commercializing proprietary diagnostic products. This is only the beginning of our journey towards cutting-edge medical achievements,” said Dr. Dennis Makarawung, MD, PhD, the Company's Medical Director.One presentation...
Nasdaq GlobeNewswire
13/09/2024
Endo Presents Data at the American Orthopaedic Foot & Ankle Society Annual…
The oral presentation covered data from the Phase 2 clinical study of CCH in patients with plantar fibromatosis. The oral presentation covered data from the Phase 2 clinical study of CCH in patients with plantar fibromatosis. The results of the Phase 2 plantar fibromatosis study demonstrated a trend in CCH treatment effect over placebo for reducing pain associated with the condition as measured by the Foot Function Index Total Pain subscale score, as well as nominally significant...
PR Newswire
13/09/2024
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards®…
DUBLIN, Sept. 13, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 20, 2024. Now in its seventh year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. The program will offer grants to early-career investigators who have…
PR Newswire
13/09/2024
Opening Ceremony of BMC France Office
Over the past 23 years, BMC has continually strived to improve and innovate. The company has launched representative products such as PAP devices, CPAP masks, and sleep diagnostic devices. With service centers and a data management platform, BMC has achieved significant success in China, and its products are now sold in over 100 countries and regions. Over the past 23 years, BMC has continually strived to improve and innovate. The company has launched representative products such as PAP...
PR Newswire
13/09/2024
Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine
First mpox vaccine to obtain prequalification by the WHOApproval will help accelerate access to the vaccine for all African countries COPENHAGEN, Denmark, September 13, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that the Company has obtained prequalification from the World Health Organization (WHO) for IMVANEX ®(MVA-BN ® ) as the first mpox vaccine to be added to the WHO prequalification list. MVA-BN is indicated for active immunization against smallpox, mpox, and...
Nasdaq GlobeNewswire
13/09/2024
Jeanne Penn joins Cambridge Healthcare Research as Vice President, US Commercial…
Jeanne has been providing market insights to the biopharma industry for decades. Based in Boston, she has worked for Genzyme (now Sanofi) and EMD Serono (known as Merck KGaA outside the US) leading CI, market research, and forecasting for multiple brands. Her therapy area expertise is wide, but rare disease is where her heart will always be. Jeanne has been providing market insights to the biopharma industry for decades. Based inBoston, she has worked for Genzyme (now Sanofi) and EMD Serono...
PR Newswire
13/09/2024
ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight
As the ESMO 2024 annual meeting approaches, numerous pharmaceutical companies are preparing to present their latest data. DelveInsight invites you to discover the newest developments in oncology research and development. As the ESMO 2024 annual meeting approaches, numerous pharmaceutical companies are preparing to present their latest data. DelveInsight invites you to discover the newest developments in oncology research and development. The DelveInsight team is ready to provide exceptional...
PR Newswire
13/09/2024
Notification of managers' transactions
ANNOUNCEMENT NO. 274 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CFO Kim Nicolajsen in the attached PDF document.For further information, please contact:Kim Nicolajsen, CFO...
Nasdaq GlobeNewswire
13/09/2024
Kine Sciences Announces First Patient Dosed in the Phase 1b/2a Study in Patients…
KINE-101 is a novel nanopeptide and a disease modifier that controls both humoral immunity and cell-mediated immune responses by activating Treg cells. KINE-101 received FDA clearance for the Phase I study on September, 2021. The study was conducted in 40 healthy individuals in five cohorts assessed over 42 days. The design included four cohorts receiving intravenously administered ascending doses of KINE-101 (10, 30, 100, and 300 mg), and a cohort that received 96.8 mg of KINE-101…
PR Newswire
13/09/2024
Valneva Announces the Success of its Private Placement Raising approximately €60…
Saint-Herblain (France), September 13, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000. Peter Bühler, Valneva's Chief Financial Officer, commented, “We would like to thank our existing shareholders for their continued support, as well as the new healthcare specialist investors joining us through this...
Nasdaq GlobeNewswire
13/09/2024
Altri Comunicati